CN112890195A - 一种增强免疫力功能中药保健品 - Google Patents
一种增强免疫力功能中药保健品 Download PDFInfo
- Publication number
- CN112890195A CN112890195A CN202110214723.1A CN202110214723A CN112890195A CN 112890195 A CN112890195 A CN 112890195A CN 202110214723 A CN202110214723 A CN 202110214723A CN 112890195 A CN112890195 A CN 112890195A
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- chinese medicine
- parts
- function
- enhancing immunity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 54
- 230000036039 immunity Effects 0.000 title claims abstract description 27
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 20
- 230000036541 health Effects 0.000 title claims description 19
- 239000002994 raw material Substances 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 239000003292 glue Substances 0.000 claims abstract description 8
- 241000191896 Rana sylvatica Species 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims abstract description 6
- 210000003056 antler Anatomy 0.000 claims abstract description 5
- 239000002552 dosage form Substances 0.000 claims abstract description 5
- 235000013361 beverage Nutrition 0.000 claims abstract description 3
- 239000002775 capsule Substances 0.000 claims abstract description 3
- 239000008187 granular material Substances 0.000 claims abstract description 3
- 239000007787 solid Substances 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 239000000047 product Substances 0.000 claims description 21
- 238000002156 mixing Methods 0.000 claims description 18
- 238000002791 soaking Methods 0.000 claims description 18
- 239000012153 distilled water Substances 0.000 claims description 16
- 241001550206 Colla Species 0.000 claims description 11
- 241000209020 Cornus Species 0.000 claims description 11
- 238000000227 grinding Methods 0.000 claims description 10
- 210000003101 oviduct Anatomy 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 7
- 230000000694 effects Effects 0.000 abstract description 23
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 235000013305 food Nutrition 0.000 abstract description 5
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 23
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 17
- 229960004397 cyclophosphamide Drugs 0.000 description 17
- 230000006870 function Effects 0.000 description 16
- 210000000952 spleen Anatomy 0.000 description 16
- 239000002609 medium Substances 0.000 description 13
- 238000011725 BALB/c mouse Methods 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 206010057249 Phagocytosis Diseases 0.000 description 12
- 230000008782 phagocytosis Effects 0.000 description 12
- 210000000683 abdominal cavity Anatomy 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000007928 intraperitoneal injection Substances 0.000 description 7
- 210000000822 natural killer cell Anatomy 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 239000012981 Hank's balanced salt solution Substances 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 229940000406 drug candidate Drugs 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 239000003777 experimental drug Substances 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 238000000465 moulding Methods 0.000 description 6
- 230000000242 pagocytic effect Effects 0.000 description 6
- 210000001541 thymus gland Anatomy 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 3
- 108010062580 Concanavalin A Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000002951 depilatory effect Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- JORABGDXCIBAFL-UHFFFAOYSA-M iodonitrotetrazolium chloride Chemical compound [Cl-].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C=CC=CC=2)=N1 JORABGDXCIBAFL-UHFFFAOYSA-M 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 206010000349 Acanthosis Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101000970399 Drosophila melanogaster Nuclear pore complex protein Nup154 Proteins 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 241001632410 Eleutherococcus senticosus Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000030984 MIRAGE syndrome Diseases 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000270930 Rana japonica Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102400000160 Thymopentin Human genes 0.000 description 1
- 101800001703 Thymopentin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000722921 Tulipa gesneriana Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- -1 compound vitamin Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- WIPCMBDEWMKHCR-UHFFFAOYSA-N dimethyl sulfate;phenazine Chemical compound COS(=O)(=O)OC.C1=CC=CC2=NC3=CC=CC=C3N=C21 WIPCMBDEWMKHCR-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- GKQWYZBANWAFMQ-UHFFFAOYSA-M lithium;2-hydroxypropanoate Chemical compound [Li+].CC(O)C([O-])=O GKQWYZBANWAFMQ-UHFFFAOYSA-M 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229960001163 pidotimod Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- TVLSRXXIMLFWEO-UHFFFAOYSA-N prochloraz Chemical compound C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl TVLSRXXIMLFWEO-UHFFFAOYSA-N 0.000 description 1
- 230000003236 psychic effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- PSWFFKRAVBDQEG-YGQNSOCVSA-N thymopentin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PSWFFKRAVBDQEG-YGQNSOCVSA-N 0.000 description 1
- 229960004517 thymopentin Drugs 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/65—Amphibians, e.g. toads, frogs, salamanders or newts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种有助于增强免疫力功能中药保健品,属于保健品技术领域。本发明由下述中药原料制成:林蛙油,刺五加,鹿角胶。优选下述重量份数范围的中药原料:林蛙油1.5~4份、刺五加4.5~15份、鹿角胶1.5~3份。本发明以中药及药食同源类食品配伍,无副作用,长期食用不仅可以达到增强免疫力效果,还可以有效调节机体,达到标本兼治的的效果;并且性状较为温和,是一种理想的增强免疫力保健品,且剂型较灵活,可根据不同患者需求制成更便利的剂型,包括颗粒剂、胶囊剂、煎膏剂口服液或固体饮料等。
Description
技术领域
本发明涉及一种增强免疫力功能中药保健品,属于保健品技术领域。
背景技术
中医认为“阴平阳秘,精神乃治”,《素问遗篇·刺法论》中也有“正气内存,邪不可干,内外调和,邪不能害”的论述,可见阴阳平衡在维持机体生理活动中具有极其重要的作用,阴阳失衡,机体抵抗力减弱则导致疾病的发生,这与现代医学对于免疫的认识是一致的。疾病由一个阶段进展到另一个阶段的过程,都是对疾病当下阶段阴阳平衡稳态的打破,每个阶段都有各自的阴阳属性,即阴阳之中复有阴阳。
人体的免疫系统是覆盖全身的防卫网络,它的功能主要有:抵御细菌病毒等致病性微生物的侵入,防止疾病发生;清除人体内的衰老、死亡、损伤的细胞;修补随时识别和清除人体内产生的异常细胞,如肿瘤细胞等。在我们日常诊疗活动中,经常有患者询问如何提高“免疫力”,其实人体的免疫系统犹如中医之“阴阳”,存在一种动态平衡,这种平衡一旦被打破,就会产生很多疾病。比如当部分免疫功能减弱时,容易导致感染甚至肿瘤;但若免疫识别功能出现障碍,免疫系统开始攻击自身器官,就会出现自身免疫性疾病,临床较为常见的如系统性红斑狼疮、类风湿关节炎、干燥综合征,甚至是发病率较高的复发性口腔溃疡。
目前临床中多用含高蛋白﹑维生素﹑高锌的食物或者服用匹多莫德口服液,或者免疫球蛋白、丙种球蛋白,以及胸腺五肽、复合维生素或者复合微量元素等药物来提高免疫力。但是鉴于效果不明显以及缺乏科学的理论指导,不能充分体现保健功能的作用特征、量效关系、作用机制,因此,亟待提出适宜于中药复方保健食品的保健功能药物。
林蛙油具有补肾益精、平肝养胃的作用,对神疲乏力、阴虚体弱、心悸失眠、盗汗不止有较好的疗效,具有较高的经济营养价值及显著的保健功效。其富含氨基酸和蛋白质,且含有矿物质和大量的维生素,是一种广谱免疫调节剂和增效剂。
刺五加补气健脾,补肾安神,归脾、肾、心经;作为补中益气、升阳固表中药,其所含的多糖、苷类等具有显著的免疫增强作用。
鹿角胶具有温补肝肾,益精养血的作用。其为补阳之上品,所含有的氨基酸及多种活性成分,对身体有补益作用,能增强体质,有效的提高机体免疫力。
本研究选取了三味药食同源的药材,在无副作用的基础上,结合中医理论中的阴阳平衡,研制出了一种具有扶正固本﹑益气健脾具有提高免疫功能的保健品。其副作用小﹑药效稳定,适宜长期服用。
发明内容
本发明的目的是提供一种增强免疫力功能中药保健品及其制备方法。
本发明的目的是通过以下技术方案来实现的:
一种增强免疫力功能中药保健品,由下述中药原料制成:林蛙油、刺五加、鹿角胶;
优选由下述重量份数的中药原料制成:林蛙油1.5~4份、刺五加4.5~15份、鹿角胶1.5~3份;
优选由下述重量份数比的中药原料制成:林蛙油:刺五加:鹿角胶=4:11:3。
上述一种增强免疫力功能中药保健品制备方法,包括如下步骤:
将中药原料刺五加中加入12倍份的蒸馏水,浸泡半小时,然后煎煮3次,每次煎煮1小时,合并煎液;趁热过滤,除去滤渣,将滤液浓缩至适当体积;将中药原料林蛙油加适量水泡发,球磨机研磨,与刺五加浓缩液混合后煎煮1小时,煎煮至40分钟时加入中药原料鹿角胶制备成膏滋,制得增强免疫力功能中药保健品。
上述中药或药食同源类中药均可以通过商业途径购买得到。
将药学上可接受用量的本发明药物组合物与药学上可接受的载体或添加剂配合后,按本领域常规的制剂方法将其制备成任意一种适宜的口服制剂。所述增强免疫力功能中药保健品的的剂型还可以为颗粒剂、胶囊剂、煎膏剂口服液或固体饮料等制剂形式。
本发明的有益效果为:一种增强免疫力功能中药保健品,以中药及药食同源类食品配伍,无副作用,长期食用不仅可以达到增强免疫力功能效果,还可以有效调节机体,达到标本兼治的效果;将林蛙油、刺五加及鹿角胶灵活配伍用以增强免疫力功能,该组方可以从调节细胞免疫、体液免疫及全身免疫等多方面作用来增强免疫力功能,而且性状较为温和,疗效稳定,副作用小,是一种理想的增强免疫力功能保健品,且剂型较灵活,效果好,服用方便。
具体实施方式
下面结合实施例对本发明进一步说明。
实施例一
下述重量份数比的中药原料林蛙油:刺五加:鹿角胶=4:11:3。将中药原料刺五加中加入12倍份的蒸馏水,浸泡半小时,然后煎煮3次,每次煎煮1小时,合并煎液;趁热过滤,除去滤渣,将滤液浓缩至适当体积;将中药原料林蛙油加适量水泡发,球磨机研磨,与刺五加浓缩液混合后煎煮1小时,煎煮至40分钟时加入中药原料鹿角胶制备成膏滋,制得增强免疫力功能中药保健品。
实施例二
1.实验动物:BALB/c小鼠40只
2.实验周期:30d
3.仪器与材料:分析天平,全血细胞分析仪
4.实验药物:
中药原料刺五加中加入12倍份的蒸馏水,浸泡半小时,然后煎煮3次,每次煎煮1小时,合并煎液;趁热过滤,除去滤渣,将滤液浓缩至适当体积;将中药原料林蛙油加适量水泡发,球磨机研磨,与刺五加浓缩液混合后煎煮1小时,煎煮至40分钟时加入中药原料鹿角胶,制成灌胃体积,内含人体推荐量的5倍、10倍、20倍生药量。
5.造模方法:环磷酰胺腹腔注射
6.检测指标:
脾指数,胸腺指数,小鼠外周血白细胞总数
7.实验方法:
50只BALB/c小鼠分为空白组、模型组、高、中、低剂量给药组,高、中、低剂量给药组,每天给予人体推荐量的20倍、10倍、5倍生药量的药物溶液,空白组和模型组给予等量蒸馏水,共给药30天,给药23天后模型组及给药组腹腔注射环磷酰,连续三天,末次注射给药5天后用电子天平精确称取小鼠体重,以摘除小鼠眼球的方法采集全血,让血液自由滴入装有抗凝剂的1.5ml离心管中,并于2h内以全血细胞分析仪检测白细胞总数。处死小鼠,取胸腺和脾脏称重,并计算胸腺和脾脏指数。按如下公式计算:胸腺指数或脾脏指数=胸腺或脾脏质量(mg)/体重(g)×10。
注:与模型组比较,*p<0.05,**p<0.01
与空白对照组比,模型组脏器指数和白细胞总数极显著降低(p<0.01);与模型组比,高剂量和中剂量给药组脏器指数显著升高(p<0.05),白细胞总数极显著升高(p<0.01)。表明该受试物可使环磷酰胺免疫抑制小鼠白细胞总数和胸腺、脾脏指数均明显升高,能有效促进外周血白细胞和免疫器官的增殖效应,该实验结果阳性。
实施例三
1.实验动物:BALB/c小鼠30只
2.实验周期:30d
3.仪器与材料:
RPMI1640细胞培养液、胎牛血清、青霉素-链霉素混合液、刀豆蛋白A(ConA)、盐酸、异丙醇、MTT、Hank's液、PBS缓冲液(pH7.2-7.4)
200目筛网、24孔培养板,96孔培养板(平底),手术器械、二氧化碳培养箱、酶标仪、超净工作台、高压灭菌器、无菌滤器。
4.实验药物:
中药原料刺五加中加入12倍份的蒸馏水,浸泡半小时,然后煎煮3次,每次煎煮1小时,合并煎液;趁热过滤,除去滤渣,将滤液浓缩至适当体积;将中药原料林蛙油加适量水泡发,球磨机研磨,与刺五加浓缩液混合后煎煮1小时,煎煮至40分钟时加入中药原料鹿角胶,制成灌胃体积,内含人体推荐量的5倍、10倍、20倍生药量。
5.造模方法:环磷酰胺腹腔注射
6.检测指标:
淋巴细胞的增殖能力
7.实验方法:
50只BALB/c小鼠分为空白组、模型组、高、中、低剂量给药组,高、中、低剂量给药组,每天给予人体推荐量的20倍、10倍、5倍生药量的药物溶液,空白组和模型组给予等量蒸馏水,共给药30天,给药23天后模型组及给药组腹腔注射环磷酰,连续三天,末次注射给药5天后,无菌取脾,置于盛有适量无菌Hank's液平皿中,轻轻将脾磨碎,制成单个细胞悬液。经200目筛网过滤用Hank's液洗2次,每次离心10min(1000r/min)。然后将细胞悬浮于1mL的完全培养液中,用台酚兰染色计数活细胞数(应在95%以上),调整细胞浓度为3×106个/mL。将每一份脾细胞悬液分两孔加入24孔培养板中,每孔1mL,一孔加75μL ConA液(相当于7.5μg/mL),另一孔作为对照,置5%CO2,37℃CO2孵箱中培养72h。培养结束前4h,每孔轻轻吸去上清液0.7mL,加入0.7mL不含小牛血清的RPMI1640培养液,同时加入MTT(5mg/mL)50μL/孔,继续培养4h。培养结束后,每孔加入1mL酸性异丙醇,吹打混匀,使紫色结晶完全溶解。然后分装到96孔培养板中,每个孔作3个平行孔,用酶标仪,以570nm波长测定光密度值。用加ConA孔的光密度值减去不加ConA孔的光密度值代表淋巴细胞的增殖能力。
注:与模型组比较,*p<0.05,**p<0.01
与空白对照组比,模型组光密度差值极显著降低(p<0.01);与模型组比,高剂量和中剂量给药组光密度差值显著升高(p<0.05)。表明该受试物可增强环磷酰胺免疫抑制小鼠脾淋巴细胞的增殖转化能力,该实验结果阳性。
实施例四
1.实验动物:BALB/c小鼠40只
2.实验周期:30d
3.仪器与材料:
DNFB、丙酮、麻油、脱毛膏、打孔器。
4.实验药物:
中药原料刺五加中加入12倍份的蒸馏水,浸泡半小时,然后煎煮3次,每次煎煮1小时,合并煎液;趁热过滤,除去滤渣,将滤液浓缩至适当体积;将中药原料林蛙油加适量水泡发,球磨机研磨,与刺五加浓缩液混合后煎煮1小时,煎煮至40分钟时加入中药原料鹿角胶,制成灌胃体积,内含人体推荐量的5倍、10倍、20倍生药量。
5.造模方法:环磷酰胺腹腔注射
6.检测指标:
耳肿胀的程度
7.实验方法:50只BALB/c小鼠分为空白组、模型组、高、中、低剂量给药组,高、中、低剂量给药组,每天给予人体推荐量的20倍、10倍、5倍生药量的药物溶液,空白组和模型组给予等量蒸馏水,共给药30天,给药23天后模型组及给药组腹腔注射环磷酰,连续三天,每鼠腹部皮肤用脱毛膏脱毛,范围约3cm×3cm、用DNFB溶液50μl均匀涂抹致敏。5天后,用DNFB溶液10μl均匀涂抹于小鼠右耳(两面)进行攻击。攻击后24h颈椎脱臼处死小鼠,剪下左右耳壳。用打孔器取下直径8mm的耳片,称重。用左右耳重量之差表示DTH的程度。
注:与模型组比较,*p<0.05
与空白对照组比,模型组左右耳片重量差值显著降低(p<0.05);与模型组比,高剂量和中剂量给药组左右耳片重量差值显著升高(p<0.05)。表明该受试物可增强环磷酰胺免疫抑制小鼠迟发型变态反应程度,该实验结果阳性。
实施例五
1.实验动物:BALB/c小鼠40只
2.实验周期:30d
3.仪器与材料:
全自动酶标仪、计时器、印度墨汁、Na2CO3。
4.实验药物:
中药原料刺五加中加入12倍份的蒸馏水,浸泡半小时,然后煎煮3次,每次煎煮1小时,合并煎液;趁热过滤,除去滤渣,将滤液浓缩至适当体积;将中药原料林蛙油加适量水泡发,球磨机研磨,与刺五加浓缩液混合后煎煮1小时,煎煮至40分钟时加入中药原料鹿角胶,制成灌胃体积,内含人体推荐量的5倍、10倍、20倍生药量。
5.造模方法:环磷酰胺腹腔注射
6.检测指标:
吞噬指数
7.实验方法:
50只BALB/c小鼠分为空白组、模型组、高、中、低剂量给药组,高、中、低剂量给药组,每天给予人体推荐量的20倍、10倍、5倍生药量的药物溶液,空白组和模型组给予等量蒸馏水,共给药30天,给药23天后模型组及给药组腹腔注射环磷酰,连续三天,末次注射给药5天后,称体重,从小鼠尾静脉注入稀释的印度墨汁,按每10g体重0.1mL计算。待墨汁注入,立即计时。注入墨汁后2、12min,分别从内眦静脉丛取血20μl,并立即将其加到2mL 0.1%Na2CO3溶液中。用全自动酶标仪在600nm波长处测光密度值(OD),以Na2CO3溶液作空白对照。将小鼠处死,取肝脏和脾脏,用滤纸吸干脏器表面血污,称重。以吞噬指数表示小鼠碳廓清的能力。
注:与模型组比较,*p<0.05,**p<0.01
与空白对照组比,模型组吞噬指数α极显著降低(p<0.01);与模型组比,高中低剂量各给药组吞噬指数α均显著升高(p<0.05)。表明该受试物可增强环磷酰胺免疫抑制小鼠碳廓清的能力,该实验结果阳性。
实施例六
1.实验动物:BALB/c小鼠40只
2.实验周期:30d
3.仪器与材料:
显微镜、37℃孵箱、计数器、手术器械一套、注射器、载玻片、染色槽、试管
4.实验药物:
中药原料刺五加中加入12倍份的蒸馏水,浸泡半小时,然后煎煮3次,每次煎煮1小时,合并煎液;趁热过滤,除去滤渣,将滤液浓缩至适当体积;将中药原料林蛙油加适量水泡发,球磨机研磨,与刺五加浓缩液混合后煎煮1小时,煎煮至40分钟时加入中药原料鹿角胶,制成灌胃体积,内含人体推荐量的5倍、10倍、20倍生药量。
5.造模方法:环磷酰胺腹腔注射
6.检测指标:
吞噬指数
7.实验方法:
50只BALB/c小鼠分为空白组、模型组、高、中、低剂量给药组,高、中、低剂量给药组,每天给予人体推荐量的20倍、10倍、5倍生药量的药物溶液,空白组和模型组给予等量蒸馏水,共给药30天,给药23天后模型组及给药组腹腔注射环磷酰,连续三天,实验前4天给每只小鼠腹腔注射2%压积羊血红细胞0.2mL。用颈椎脱臼法处死小鼠,腹腔注射加小牛血清的Hank's液4mL/只,轻轻按揉腹部20次,以充分洗出腹腔巨噬细胞,然后将腹壁剪开一个小口,用注射器吸取腹腔洗液2mL于试管内。用1mL加样器吸取腹腔洗液0.5mL加入盛有0.5mL1%鸡血红细胞悬液的试管内,混匀。用注射器(装大针头)吸取0.5mL混合液,加入玻片的琼脂圈内。放置孵箱内37℃孵育15-20分钟。孵育结束后迅速用生理盐水将未贴壁细胞冲掉,于甲醇液中固定1分钟,Giemsa液染色15分钟。用蒸馏水冲洗干净,晾干,用40×显微镜计数吞噬率和吞噬指数。吞噬率为每100个巨噬细胞中,吞噬鸡红细胞的巨噬细胞所占的百分率;吞噬指数为平均每个巨噬细胞吞噬鸡红细胞的个数。
注:与模型组比较,*p<0.05,**p<0.01
与空白对照组比,模型组巨噬细胞吞噬率和吞噬指数极显著降低(p<0.01);与模型组比,高剂量和中剂量给药组巨噬细胞吞噬率和吞噬指数极显著升高(p<0.01)。表明该受试物可增强环磷酰胺免疫抑制小鼠巨噬细胞吞噬率和吞噬指数,该实验结果阳性。
实施例七
1.实验动物:BALB/c小鼠30只
2.实验周期:30d
3.仪器与材料:
酶标仪、YAC-1细胞、Hank's液(pH7.2~7.4)、RPMI1640完全培养液、乳酸锂、碘硝基氯化四氮唑蓝(INT)、吩嗪二甲酯硫酸盐(PMS)、NAD、0.2mol/L的Tris-HCl缓冲液(pH8.2)、2.5%Triton。
4.实验药物:
中药原料刺五加中加入12倍份的蒸馏水,浸泡半小时,然后煎煮3次,每次煎煮1小时,合并煎液;趁热过滤,除去滤渣,将滤液浓缩至适当体积;将中药原料林蛙油加适量水泡发,球磨机研磨,与刺五加浓缩液混合后煎煮1小时,煎煮至40分钟时加入中药原料鹿角胶,制成灌胃体积,内含人体推荐量的5倍、10倍、20倍生药量。
5.造模方法:环磷酰胺腹腔注射
6.检测指标:
NK细胞活性
7.实验方法:
50只BALB/c小鼠分为空白组、模型组、高、中、低剂量给药组,高、中、低剂量给药组,每天给予人体推荐量的20倍、10倍、5倍生药量的药物溶液,空白组和模型组给予等量蒸馏水,共给药30天,给药23天后模型组及给药组腹腔注射环磷酰,连续三天,末次注射给药5天后,无菌取脾,置于盛有适量无菌Hank's液的小平皿中,轻轻将脾磨碎,制成单细胞悬液。经200目筛网过滤,用Hank's液洗2次,每次离心10min(1000r/min)。弃上清将细胞浆弹起,采用NH4Cl-Tris红细胞裂解液裂解红细胞,离心10min(1000r/min),弃红色上清。用1mL含10%小牛血清的RPMI1640完全培养液重悬,用台酚兰染色计数活细胞数(应在95%以上),最后用RPMI1640完全培养液调整细胞浓度为2×107个/mL。实验前24h将靶细胞进行传代培养。用前以Hank's液洗3次,用RPMI1640完全培养液调整细胞浓度为4×105个/mL。取靶细胞和效应细胞各100μL(效靶比50:1),加入U型96孔培养板中;靶细胞自然释放孔加靶细胞和培养液各100μL,靶细胞最大释放孔加靶细胞和2.5%Triton各100μL;上述各项均设三个平行孔,于37℃、5%CO2培养箱中培养4h,然后将96孔培养板以1500r/min离心5min,每孔吸取上清100μL置平底96孔培养板中,同时加入LDH基质液100μL,根据室温不同反应3~10min,每孔加入1mol/L的HCl 30μL,在酶标仪490nm处测定光密度值(OD)。NK细胞活性%=[(反应孔OD-自然释放孔OD)/(最大释放孔OD-自然释放孔OD)]×100%
注:与模型组比较,*p<0.05,**p<0.01
与空白对照组比,模型组NK细胞活性极显著降低(p<0.01);与模型组比,高剂量和中剂量给药组NK细胞活性极显著升高(p<0.01),低剂量给药组NK细胞活性显著升高(p<0.05)表明该受试物可增强环磷酰胺免疫抑制小鼠NK细胞活性,该实验结果阳性。
Claims (5)
1.一种增强免疫力功能中药保健品,其特征在于:由下述中药原料制成:林蛙油、刺五加、鹿角胶。
2.根据权利要求1所述的一种增强免疫力功能中药保健品,其特征在于:由下述重量份数的中药原料制成:林蛙油1.5~4份、刺五加4.5~15份、鹿角胶1.5~3份。
3.根据权利要求1所述的一种增强免疫力功能中药保健品,其特征在于:各中药原料的重量份数比为:林蛙油:刺五加:鹿角胶=4:11:3。
4.根据权利要求1-3任一项所述的一种增强免疫力功能中药保健品的制备方法,其特征在于:将中药原料刺五加中加入12倍份的蒸馏水,浸泡半小时,然后煎煮3次,每次煎煮1小时,合并煎液;趁热过滤,除去滤渣,将滤液浓缩至适当体积;将中药原料林蛙油加适量水泡发,球磨机研磨,与刺五加浓缩液混合后煎煮1小时,煎煮至40分钟时加入中药原料鹿角胶制备成膏滋,制得增强免疫力功能中药保健品。
5.根据权利要求4所述的一种增强免疫力功能中药保健品的制备方法,其特征在于:所述增强免疫力功能中药保健品的的剂型还可以为颗粒剂、胶囊剂、煎膏剂口服液或固体饮料。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110214723.1A CN112890195A (zh) | 2021-02-25 | 2021-02-25 | 一种增强免疫力功能中药保健品 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110214723.1A CN112890195A (zh) | 2021-02-25 | 2021-02-25 | 一种增强免疫力功能中药保健品 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112890195A true CN112890195A (zh) | 2021-06-04 |
Family
ID=76108431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110214723.1A Pending CN112890195A (zh) | 2021-02-25 | 2021-02-25 | 一种增强免疫力功能中药保健品 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112890195A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101049449A (zh) * | 2007-05-16 | 2007-10-10 | 李世杰 | 一种利用中药和淋巴细胞抗原体联合增效对恶性肿瘤进行免疫治疗的中药组合物 |
CN101444273A (zh) * | 2007-11-22 | 2009-06-03 | 何煜 | 一种保健品口腔速释制剂及其制造方法 |
CN102114067A (zh) * | 2010-04-30 | 2011-07-06 | 吉林医药学院 | 复方林蛙油冲剂及其应用 |
CN102511799A (zh) * | 2011-12-15 | 2012-06-27 | 高耸 | 胶凝状林蛙油保健食品及其制作方法 |
CN105125845A (zh) * | 2015-09-06 | 2015-12-09 | 吉林大学 | 一种改善睡眠状况的保健食品 |
CN110680850A (zh) * | 2019-12-02 | 2020-01-14 | 黑龙江中医药大学 | 一种降血脂中药保健品 |
-
2021
- 2021-02-25 CN CN202110214723.1A patent/CN112890195A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101049449A (zh) * | 2007-05-16 | 2007-10-10 | 李世杰 | 一种利用中药和淋巴细胞抗原体联合增效对恶性肿瘤进行免疫治疗的中药组合物 |
CN101444273A (zh) * | 2007-11-22 | 2009-06-03 | 何煜 | 一种保健品口腔速释制剂及其制造方法 |
CN102114067A (zh) * | 2010-04-30 | 2011-07-06 | 吉林医药学院 | 复方林蛙油冲剂及其应用 |
CN102511799A (zh) * | 2011-12-15 | 2012-06-27 | 高耸 | 胶凝状林蛙油保健食品及其制作方法 |
CN105125845A (zh) * | 2015-09-06 | 2015-12-09 | 吉林大学 | 一种改善睡眠状况的保健食品 |
CN110680850A (zh) * | 2019-12-02 | 2020-01-14 | 黑龙江中医药大学 | 一种降血脂中药保健品 |
Non-Patent Citations (6)
Title |
---|
张争明等: "鹿源药材保健食品研发现状与方向", 《经济动物学报》 * |
张爽 等: "复方斑龙强志膏滋配比优选及其对免疫低下模型小鼠保护作用的研究", 《时珍国医国药》 * |
李晶等: "鹿角胶对环磷酰胺所致血虚模型小鼠的影响", 《吉林中医药》 * |
王彦武等: "林蛙油小鼠免疫调节作用的实验研究", 《中国当代医药》 * |
翟旭楠等: "刺五加多糖对小鼠免疫功能的影响", 《中医药信息》 * |
范颖等: "《中药药对配方理论及应用》", 31 December 2015, 辽宁科学技术出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6305407B2 (ja) | 免疫を調節する漢方薬組成物及びその製造方法 | |
US8617567B2 (en) | Fungus polyose composition with immunity enhancing effect and application thereof | |
CN112569305A (zh) | 一种提高免疫力的香菇复合多糖组合物及其制备方法 | |
CN101716256B (zh) | 一种用于增强免疫的制剂 | |
AU2016201968A1 (en) | Sporoderm-broken ganoderma lucidum spore powder, honey & propolis buccal tablet and manufacturing method thereof | |
CN108813610B (zh) | 一种用于提高免疫力的雪莲组合物及其应用 | |
CN109394809A (zh) | 一种提高免疫力的中药组合物及其制备方法和应用 | |
CN113069510A (zh) | 一种增强免疫力的组合物及其制备方法和应用 | |
CN112890195A (zh) | 一种增强免疫力功能中药保健品 | |
CN105687480A (zh) | 一种免疫调节的中药组合物及制剂 | |
CN1401365A (zh) | 一种中药保健药物 | |
CN115869370A (zh) | 一种治疗大气下陷类疾病的中药组合物及其制备方法 | |
CN113476554A (zh) | 益气补血且提高免疫力的三味胎盘膏及其制备方法 | |
CN112891492A (zh) | 一种中药首乌益髓组合物及其胶囊和膏剂的制备方法 | |
CN104524233B (zh) | 一种促进造血功能提高免疫力的生物反应调节剂及其制备与应用 | |
CN113855764A (zh) | 用于提高机体免疫力的中药复方制剂 | |
CN106214844A (zh) | 一种具有减肥和免疫调节作用的组合物及其制备方法 | |
CN113332327A (zh) | 西洋参黄芪制剂在制备提高免疫力的产品中的应用 | |
CN102784230A (zh) | 一种治疗营养性贫血的药物组合物制剂 | |
CN1421238A (zh) | 一种具有抗肿瘤、抗自由基损伤和调节免疫的天然生物反应调节剂 | |
CN1062465C (zh) | 双五降糖胶囊 | |
CN1160095C (zh) | 抗衰老养生膏及其制备方法 | |
CN102406172A (zh) | 增强免疫力的保健食品及其制备方法 | |
CN111544570B (zh) | 一种添加抗菌肽的抗病毒制剂及其制备方法 | |
CN117357627B (zh) | 一种提高家禽机体免疫力的复合药物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |